Search results
Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) incurs wider-than-estimated loss for first-quarter 2022. Sales of the sole marketed...
Clovis Oncology (CLVS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) possesses the right combination of the two key ingredients for a likely earnings beat...
Down 67.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Clovis (CLVS)
Zacks via Yahoo Finance· 1 year agoClovis (CLVS) has become technically an oversold stock now, which implies exhaustion of the heavy...
Clovis Oncology (CLVS) Reports Q2 Loss, Misses Revenue Estimates
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) delivered earnings and revenue surprises of -2.38% and 15.01%, respectively, for the...
Clovis (CLVS) Down 12.6% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 2 years agoA month has gone by since the last earnings report for Clovis Oncology (CLVS). Shares have lost...
Clovis (CLVS) Seeks Nod for Rubraca in First Line Ovarian Cancer
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) files regulatory applications in the United States and Europe seeking label expansion...
Clovis Oncology Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St. via Yahoo Finance· 1 year agoClovis Oncology (NASDAQ:CLVS) Third Quarter 2022 ResultsKey Financial Results Revenue: US$30.7m...
Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why
Zacks via Yahoo Finance· 1 year agoClovis Oncology, Inc.’s CLVS shares have plunged 49.6% in the past six months against the industry’s...
What Kind Of Shareholders Own Clovis Oncology, Inc. (NASDAQ:CLVS)?
Simply Wall St. via Yahoo Finance· 2 years agoIf you want to know who really controls Clovis Oncology, Inc. (NASDAQ:CLVS), then you'll have to...
The Clovis Oncology, Inc. (NASDAQ:CLVS) Analysts Have Been Trimming Their Sales Forecasts
Simply Wall St. via Yahoo Finance· 2 years agoToday is shaping up negative for Clovis Oncology, Inc. (NASDAQ:CLVS) shareholders, with the analysts...